Study Of Palbociclib (PD-0332991) In Renal Impairment
Launched by PFIZER · Mar 11, 2014
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Personally signed and dated informed consent document.
- • Renal function calculated by the Cockcroft Gault equation: normal function (CLcr \>=90 mL/min), mild: CLcr \>=60 mL/min and \<90 mL/min, moderate: CLcr \>=30 mL/min and \<60 mL/min, severe: CLcr \<30 mL/min but not requiring hemodialysis.
- • Subjects with normal renal function matched for age, weight, gender and race to subjects in impaired renal function groups.
- Exclusion Criteria:
- • Any condition possibly affecting drug absorption.
- • Renal allograft recipients.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Orlando, Florida, United States
Deland, Florida, United States
Saint Paul, Minnesota, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials